Substituted pyrazolo piperidine carboxylic acids

Patent metadata

Field	Value
Publication number	US-12595247-B2
Application number	US-202217667410-A
Country	US
Kind code	B2
Filing date	Feb 8, 2022
Priority date	Dec 10, 2020
Publication date	Apr 7, 2026
Grant date	Apr 7, 2026

Abstract

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

First claim

The invention claimed is:

1 . A process for preparing a compound of the formula (I) or salts thereof, solvates thereof or solvates of the salts thereof, characterized in that in a first step [D] compounds of formula (VIII)

in which
R 1 represents hydrogen or halogen,
R 2 represents hydrogen or halogen, and
R 3 represents chloro or trifluoromethyl,
are reacted with compounds of formula (VII)

in which
R 4 represents hydrogen or C 1 -C 4 -alkyl,
R 5 represents C 1 -C 6 -alkyl,
R 9 represents hydrogen, methyl or both or both R 9 groups combine to form via the adjacent oxygen atoms a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan,
X 1 represents nitrogen or carbon, and
X 2 represents nitrogen or carbon,
in the presence of a palladium source, a suitable ligand and a base to provide compounds of formula (II)

in which R 1 , R 2 , R 3 , R 4 , R 5 and X 1 and X 2 are defined as above and
in a second step [A]
compounds of formula (II)

are reacted with a base in a suitable solvent to provide compounds of formula (I),

in which R 1 , R 2 , R 3 , R 4 , R 5 and X 1 and X 2 are defined as above, and optionally compounds of formula (I) are transferred in a third step [A] * into the corresponding salts of formula (Ia)

in the presence of a suitable acid in a suitable solvent.

2 . A compound according to formula (I)

in which
R 1 represents hydrogen or halogen,
R 2 represents hydrogen or halogen,
R 3 represents chloro or trifluoromethyl,
R 4 represents hydrogen or C 1 -C 4 -alkyl,
R 5 represents C 1 -C 6 -alkyl,
X 1 represents nitrogen or carbon, and
X 2 represents nitrogen or carbon,
or a salt thereof, solvates thereof or solvates of the salts thereof
for use in the treatment and/or prophylaxis of diseases.

3 . A compound according to formula (I)

in which
R 1 represents hydrogen or halogen,
R 2 represents hydrogen or halogen,
R 3 represents chloro or trifluoromethyl,
R 4 represents hydrogen or C 1 -C 4 -alkyl,
R 5 represents C 1 -C 6 -alkyl,
X 1 represents nitrogen or carbon, and
X 2 represents nitrogen or carbon,
or a salt thereof, solvates thereof or solvates of the salts thereof
for use in the treatment and/or prophylaxis of heart failure (HFrEF, HFmrEF and HFpEF), hypertension (HTN), chronic and diabetic kidney disease (CKD, DKD), pulmonary hypertension (PH), systemic sclerosis (SSc), sickle cell disease (SCD), neurodegenerative diseases and dementias, or diabetic foot ulcer (DFU).

4 . A composition for use as a medication for the treatment and/or prophylaxis of disease comprising a compound according to formula (I)

in which
R 1 represents hydrogen or halogen,
R 2 represents hydrogen or halogen,
R 3 represents chloro or trifluoromethyl,
R 4 represents hydrogen or C 1 -C 4 -alkyl,
R 5 represents C 1 -C 6 -alkyl,
X 1 represents nitrogen or carbon, and
X 2 represents nitrogen or carbon,
or a salt thereof, solvates thereof or solvates of the salts thereof.

5 . A composition for use as a medication for the treatment and/or prophylaxis of disease comprising a compound according to formula (I)

in which
R 1 represents hydrogen or halogen,
R 2 represents hydrogen or halogen,
R 3 represents chloro or trifluoromethyl,
R 4 represents hydrogen or C 1 -C 4 -alkyl,
R 5 represents C 1 -C 6 -alkyl,
X 1 represents nitrogen or carbon, and
X 2 represents nitrogen or carbon,
or a salt thereof, solvates thereof or solvates of the salts thereof,
wherein the disease is selected from the group consisting of heart failure (HFrEF, HFmrEF and HFpEF), hypertension (HTN), chronic and diabetic kidney disease (CKD, DKD), pulmonary hypertension (PH), systemic sclerosis (SSc), sickle cell disease (SCD), neurodegenerative diseases and dementias, and diabetic foot ulcer (DFU).

6 . A medicament containing a compound of formula (I) as in claim 3 for use in the treatment and/or prophylaxis of heart failure (HFrEF, HFmrEF and HFpEF), hypertension (HTN), chronic and diabetic kidney disease (CKD, DKD), pulmonary hypertension (PH), systemic sclerosis (SSc), sickle cell disease (SCD), neurodegenerative diseases and dementias, or diabetic foot ulcer (DFU).

Assignees

• Bayer Ag

Inventors

• Vakalopoulos Alexandros
• Collin-Kröpelin Marie-Pierre
• Ortega Hernandez Nuria
• Dieskau Andre
• Boultadakis-Arapinis Melissa
• Candish Lisa
• Stellfeld Timo
• Mathar Ilka
• Hofmeister Lucas Hudson
• Sandner Peter
• Wunder Frank
• Dietz Lisa
• Webster Robert Alan
• Schmeck Carsten
• Mondritzki Thomas

Classifications

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P13/12

  of the kidneys · CPC title